Head-To-Head Comparison: GT Biopharma (NASDAQ:GTBP) and Bolt Biotherapeutics (NASDAQ:BOLT)

GT Biopharma (NASDAQ:GTBP) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Profitability

This table compares GT Biopharma and Bolt Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	-125.05%	-81.86%
Bolt Biotherapeutics	-990.43%	-47.56%	-35.64%

Valuation and Earnings

This table compares GT Biopharma and Bolt Biotherapeutics’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$20.88 million	($0.30)	-0.79
Bolt Biotherapeutics	$7.20 million	4.98	-$88.10 million	($1.89)	-0.50

GT Biopharma has higher earnings, but lower revenue than Bolt Biotherapeutics. GT Biopharma is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

8.1% of GT Biopharma shares are owned by institutional investors. Comparatively, 73.6% of Bolt Biotherapeutics shares are owned by institutional investors. 10.0% of GT Biopharma shares are owned by insiders. Comparatively, 28.4% of Bolt Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

GT Biopharma has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Bolt Biotherapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for GT Biopharma and Bolt Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	0	1	1	0	2.50
Bolt Biotherapeutics	0	1	2	0	2.67

GT Biopharma presently has a consensus target price of $3.50, indicating a potential upside of 1,386.20%. Bolt Biotherapeutics has a consensus target price of $5.67, indicating a potential upside of 499.65%. Given GT Biopharma’s higher probable upside, equities analysts clearly believe GT Biopharma is more favorable than Bolt Biotherapeutics.

Summary

Bolt Biotherapeutics beats GT Biopharma on 9 of the 13 factors compared between the two stocks.

About GT Biopharma

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.